Core Viewpoint - Jinxin Reproductive Medicine (01951) shows a positive operational trend in Q4, continuing the improvement seen in the first three quarters, with a notable increase in resilience in business operations [1] Group 1: Company Performance - The stock price of Jinxin Reproductive Medicine increased by over 7% during the trading session, closing up 5.28% at HKD 2.59, with a trading volume of HKD 165 million [1] - As of the end of 2025, the cumulative number of IVF egg retrieval cycles is expected to see a reduction in year-on-year decline from 5.2% in the first three quarters to 1.4% [1] Group 2: Industry Context - Jinxin Reproductive Medicine, as a leading player in the domestic assisted reproductive industry, is anticipated to benefit from the ongoing enhancement of fertility policies in China and the United States [1] - The company is projected to experience marginal performance improvement in 2026, supported by a low base effect [1]

Core Viewpoint - The stock of Jinxin Fertility (01951) has shown a positive trend, with a rise of over 7% during the trading session and currently up by 5.28%, indicating strong market interest and confidence in the company's performance [1] Group 1: Company Performance - Jinxin Fertility's fourth-quarter operational data continues to show improvement, following a positive trend from the previous three quarters, demonstrating resilient business operations [1] - By the end of 2025, the cumulative number of IVF egg retrieval cycles is expected to see a reduction in year-on-year decline from 5.2% in the previous three quarters to 1.4%, indicating a significant recovery in performance [1] Group 2: Market Context - As a leading player in the domestic assisted reproductive industry, Jinxin Fertility is poised to benefit from the ongoing enhancement of fertility policies in China and the United States, with expectations for marginal performance improvement in 2026 from a low base [1]